Research location
Osaka
Osaka, Japan
Advertisement
Research activity in Osaka
Osaka, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 207 trials and 299 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Osaka
207 linked trials · page 2 of 5Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)NCT04888585 · 2021-06-23 · 2 site observations
TERMINATED
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)NCT04484142 · 2021-03-30 · 2 site observations
COMPLETED
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT04699188 · 2021-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04751487 · 2021-02-12 · 2 site observations
COMPLETED
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerNCT04524000 · 2021-01-08 · 2 site observations
ACTIVE_NOT_RECRUITING
Special Drug Use-results Surveillance of Tabrecta TabletsNCT04575025 · 2020-11-02 · 4 site observations
COMPLETED
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927 · 2020-10-28 · 1 site observation
COMPLETED
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerNCT04478266 · 2020-10-14 · 2 site observations
TERMINATED
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled AsthmaNCT04410523 · 2020-09-09 · 1 site observation
TERMINATED
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)NCT04458051 · 2020-08-13 · 1 site observation
COMPLETED
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidNCT04468659 · 2020-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)NCT04410978 · 2020-06-30 · 1 site observation
COMPLETED
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).NCT04303780 · 2020-06-04 · 2 site observations
COMPLETED
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115 · 2020-04-24 · 35 site observations
COMPLETED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · 2020-03-02 · 1 site observation
TERMINATED
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956 · 2020-02-06 · 1 site observation
TERMINATED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829 · 2019-11-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412 · 2019-10-08 · 1 site observation
COMPLETED
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationNCT03930732 · 2019-04-15 · 1 site observation
COMPLETED
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanNCT03844945 · 2019-03-19 · 1 site observation
COMPLETED
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]NCT03734029 · 2018-12-27 · 1 site observation
COMPLETED
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 2 site observations
ACTIVE_NOT_RECRUITING
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation
TERMINATED
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsNCT03056755 · 2017-08-29 · 1 site observation
COMPLETED
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + TrastuzumabNCT03264547 · 2017-08-28 · 1 site observation
COMPLETED
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerNCT03090737 · 2017-06-02 · 1 site observation
COMPLETED
A Long-term Safety Study of QVM149 in Japanese Patients With AsthmaNCT03100825 · 2017-04-28 · 1 site observation
COMPLETED
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNCT03052608 · 2017-04-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11 · 1 site observation
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes StudyNCT03078036 · 2017-03-13 · 1 site observation
COMPLETED
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)NCT02998528 · 2017-03-04 · 1 site observation
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 5 site observations
COMPLETED
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationNCT02906020 · 2016-12-15 · 1 site observation
TERMINATED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation
COMPLETED
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseNCT02956486 · 2016-10-20 · 3 site observations
TERMINATED
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's DiseaseNCT02906488 · 2016-09-12 · 3 site observations
COMPLETED
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease DementiaNCT02783573 · 2016-07-01 · 2 site observations
TERMINATED
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.NCT02703636 · 2016-05-09 · 1 site observation
COMPLETED
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionNCT02695420 · 2016-04-14 · 3 site observations
COMPLETED
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)NCT02706951 · 2016-03-23 · 1 site observation
COMPLETED
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid ArthritisNCT02638948 · 2016-02-16 · 1 site observation
COMPLETED
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaNCT02554786 · 2015-12-29 · 1 site observation
COMPLETED
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyNCT02538666 · 2015-10-13 · 1 site observation
COMPLETED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseNCT02484547 · 2015-09-15 · 3 site observations
TERMINATED
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · 2015-09-14 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.